HHV-6 Suppressor Therapy for SITH-1 Mediated Mood Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for effectively treating or preventing mood disorders, particularly those linked to human herpesvirus 6 (HHV-6) infection, as they fail to address the elevated levels of SITH-1 protein and associated calcium modulating cyclophilin ligand (CAML) and calcium ions in the brain, which contribute to mental disorders.
Innovation Solution
Administering a human herpesvirus 6 suppressor, such as anti-HHV-6 drugs or virus reactivation suppressors like ganciclovir, to reduce the expression of SITH-1 and associated proteins, thereby lowering calcium levels in the brain, thereby treating or preventing mood disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to treat mood disorders, then general treatment is provided, but they fail to address the specific mechanism involving HHV-6 infection and SITH-1 protein elevation
Solution Approach 1:
The patent applies local quality by developing a treatment specifically targeted at HHV-6 infected cells expressing SITH-1 protein, rather than applying general mood disorder treatments uniformly. The suppressor agent is designed to selectively act on cells with the specific pathological characteristic of SITH-1 expression, making the treatment effective for HHV-6 related mood disorders while potentially sparing other conditions.
Solution Approach 2:
The patent utilizes parameter changes by measuring antibody levels against SITH-1 protein as a diagnostic parameter to identify patients who would benefit from the suppressor treatment. This parameter-based approach allows for personalized treatment selection, changing the treatment paradigm from general to parameter-guided specific therapy.
2Reliability
If HHV-6 suppressors are administered to reduce SITH-1 protein levels, then treatment effectiveness for HHV-6 related mood disorders is improved, but the complexity of diagnosis and treatment monitoring increases
Solution Approach 1:
The patent implements feedback by using the level of antibodies against SITH-1 protein as a diagnostic and monitoring tool. This feedback mechanism allows clinicians to identify patients who need treatment and monitor the effectiveness of the suppressor therapy, creating a closed-loop system that guides treatment decisions and adjusts therapy based on measured outcomes.
3Duration of action of stationary object
If the focus is placed on treating the underlying HHV-6 infection mechanism, then long-term prevention is improved, but immediate symptom relief may be delayed
Solution Approach 1:
The patent applies preliminary action by targeting the underlying HHV-6 infection mechanism and SITH-1 protein expression before mood disorder symptoms fully develop or recur. By suppressing viral reactivation and SITH-1 expression proactively, the treatment prevents the cascade of events leading to mood disorders, achieving long-term prevention while the feedback mechanism ensures timely intervention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The administration of HHV-6 suppressors effectively suppresses the elevation of SITH-1 and calcium levels in the brain, reducing the number of cells expressing SITH-1 and alleviating symptoms of mood disorders, providing a therapeutic approach for mood disorders associated with HHV-6 infection.
Implementation Method 1
Administering a human herpesvirus 6 suppressor, such as anti-HHV-6 drugs or virus reactivation suppressors like ganciclovir, to reduce the expression of SITH-1 and associated proteins
Implementation Method 2
an antibody against the small protein encoded by the intermediate stage transcript of HHV-6 (SITH-1) to be detected by an immunological detection method using an immunological antigen-antibody technique
Data Source
AI summary
The present invention is directed to methods of treating a subject, wherein a biological sample taken from the subject comprises an antibody against a small protein encoded by an intermediate stage transcript of HHV-6 (SITH-1), and the antibody against SITH-1 being present in an amount sufficient to be detected in the biological sample which is at least diluted 10-fold or more by an immunological detection method. Such treatment methods are used for the following: a) treating or preventing mood disorders; b) suppressing an elevation of the level of SITH-1 within cells in the subject's brain, reducing the number of cells in the brain that carry the protein SITH-1, and/or reducing the total amount of SITH-1 in the brain; c) suppressing an elevation of the level of a calcium modulating cyclophilin ligand (CAML) protein within cells in the subject's brain; or d) suppressing an elevation of the level of calcium ions within cells in the subject's brain. Methods of the present invention can involve administering a human herpesvirus 6 suppressor to a subject.